Condition
Crohn's disease news across medications, symptoms, tests, procedures, complications, research, access, and daily life.
Page 15 of 33 · 1547 articles
If hospital-treated infections raise later IBD risk—especially in people with certain immune-related genetic variants—this supports a multi-hit model of IBD and could eventually help identify higher-risk individuals...
The study suggests upadacitinib may improve both symptoms and MRI‑documented healing of perianal fistulas in Crohn’s disease, offering a potential treatment option especially for patients who have not previously received...
Postoperative recurrence after ileal resection is common in Crohn’s disease; understanding microbial changes linked to recurrence could help explain mechanisms and guide future biomarker development.
The project could reveal a new neuro-immune circuit (IL-17A acting on enteric neurons) that promotes tissue protection during intestinal inflammation, suggesting novel non-immunosuppressive therapeutic targets for IBD.
This FDA label update adds or confirms ABRILADA (an adalimumab product) as an approved TNF-blocker option for Crohn’s disease (including children ≥6) and ulcerative colitis (adults). It emphasizes infection and...
Bile acids shape immune signaling in the gut, and this project investigates how altered bile acid pools during ileitis could contribute to Crohn’s disease—knowledge that might point to new biomarkers or treatment...
The label confirms adalimumab is approved for Crohn’s disease and ulcerative colitis and includes boxed safety warnings—information that directly affects patients considering or taking this TNF‑blocking biologic.
This is an FDA drug-label record for ustekinumab that lists approved uses for Crohn’s disease and ulcerative colitis and highlights safety precautions (infections, TB screening, malignancy risk, and vaccine...
An FDA label update names risankizumab (SKYRIZI) as a treatment option for adults with moderately to severely active Crohn’s disease and ulcerative colitis and highlights new or emphasized safety monitoring (liver tests,...
This project studies a novel enzyme target (GCPII) that is reportedly upregulated in IBD and may change glutamate signaling and barrier function; understanding it could point to new treatment strategies for people whose...
Intestinal fibrosis and strictures remain a major cause of surgery and obstruction in Crohn’s disease, and current anti-inflammatory drugs don’t reliably prevent fibrosis. If microbial choline degradation promotes...
Children with Crohn’s disease have fewer FDA‑approved advanced treatment options than adults, so clinicians and families often must choose among off‑label therapies with limited pediatric evidence.
This is an FDA label entry for YUFLYMA (an adalimumab product) that confirms Crohn’s disease and ulcerative colitis are listed indications and reiterates serious-infection and malignancy warnings for TNF blockers....
FUT enzymes affect mucosal immunity and have been associated with Crohn's disease and other IBDs; understanding their function could reveal new biological mechanisms and future therapeutic targets.
This study examines a combination of ustekinumab plus low‑dose upadacitinib for patients with refractory Crohn’s disease — a group with limited options after failing anti‑TNF and single‑agent therapy. Results could...
This trial is testing an investigational anti-TL1A antibody (tulisokibart/MK-7240) as a potential new treatment for moderate to severe Crohn's disease. Results could affect future treatment options if the drug proves...
A successful Phase 3 trial could provide a new treatment option specifically studied in children with moderate‑to‑severe Crohn's disease, addressing a pediatric population often underrepresented in trials.
The trial is testing risankizumab alone and in combination with investigational ABBV antibodies for moderate-to-severe Crohn’s disease and ulcerative colitis — findings could inform future treatment choices and...
Small-bowel Crohn's disease often causes strictures and fistulas and typically needs more imaging and procedural care than colonic disease, so patients and clinicians should be aware of its distinct risks and treatment...
The study suggests measurable retinal and choroidal microvascular differences in people with IBD versus controls, which could point to systemic vascular effects of inflammation and offer noninvasive biomarker...
An obituary listing Crohn’s disease and ulcerative colitis as the cause of death is a personal account that can resonate with others affected by IBD and highlights real-world impact on individuals and families.
Cure8 found this source from academic.oup.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Ileocecal Resection, and Procedures and surgery. Open the original article for the full...
This review explains how genetic, microbial, immune, and stromal factors interact to cause Crohn’s disease, which helps explain why treatments often need to target specific immune pathways or biologic mechanisms....
Dietary strategies such as the Crohn’s Disease Exclusion Diet (CDED) may help induce remission for some people with Crohn’s disease and could be an option alongside medical therapy or enteral nutrition. Patients...
Based on the title and source metadata, this appears to be a case report related to Crohn's disease, Upadacitinib, and JAK inhibitor. The original article is from JAAD case reports.
The study identifies a sizable group of patients in Latin America with difficult-to-treat IBD—especially Crohn’s disease—highlighting higher disease severity, younger onset, and longer diagnostic delays that can affect...
Researchers are exploring circRNAs as new molecular players in IBD inflammation; that could lead to future biomarker tests or novel treatments targeting immune pathways relevant to Crohn’s disease and ulcerative colitis.
Based on the title and source metadata, this appears to be a case report related to Crohn's disease, Adalimumab, and Anti-TNF. The original article is from Journal of Crohn's & colitis.
Work participation and job retention are common concerns for people living with IBD. This study will measure how IBD affects work ability, fatigue, mental health, and return-to-work barriers, and aims to create...
The study is comparing common biologics given after Crohn's surgery to prevent endoscopic recurrence—a key issue for people who have had bowel resection. Knowing which drugs perform better in real‑world practice could...
A long-term study that profiles immune cells, genes, diet, and the microbiome could help identify biomarkers that predict flares or response to therapy, which matters to people living with Crohn’s or ulcerative colitis.
Mentions of Crohn’s disease in obituaries can be relevant to the IBD community as they reflect lived experience and may help raise awareness about disease burden and comorbidities.
Malnutrition is common in Crohn’s disease and more likely during active disease; recognizing it matters because nutritional status affects symptoms, recovery, and treatment tolerance.
Researchers identify a gut microbe (Sutterella species) that may worsen intestinal inflammation by blocking AhR-driven IL-22 and IL-17 responses—pathways that help protect the gut lining.
If validated, a blood test for cytotoxic CD4+ T cells at diagnosis could help predict who is less likely to respond to anti‑TNF drugs, potentially allowing earlier selection of alternative therapies for some children...
The study shows rapidly rising IBD healthcare costs driven mainly by growing prevalence and biologic therapy spending, which can affect access, insurance coverage, and healthcare planning for people with Crohn’s and...
This paper links specific features of the gut bacterial flagellome to TLR5-driven immune activation and reports a disease-associated shift in flagellin profiles in Crohn’s disease and ulcerative colitis, suggesting...
This NIH natural-history study is collecting clinical, immune, and genetic samples from people with Crohn’s disease and ulcerative colitis to better understand immune pathways and molecular causes of IBD. Those findings...
Mucosal healing is an important treatment goal linked to better long-term outcomes, and current anti-TNF therapies achieve mucosal healing in a minority of patients. If adding CDED improves healing, it could offer a...
Adding structured partial enteral nutrition to advanced drug therapy could offer a non-pharmacologic way to improve short-term, steroid-free remission rates in active Crohn's disease if the trial shows benefit.
Genetic primary bile acid malabsorption can produce IBD-like symptoms and may be missed in children labeled with Crohn's disease; recognizing PBAM could change testing and management for some patients.
Understanding and quantifying placebo-driven endoscopic changes can improve design and interpretation of Crohn’s disease trials, which may ultimately speed development of effective therapies and clarify who benefits from...
Capsule endoscopy can be helpful for small-bowel assessment in Crohn’s disease but carries a risk of retention when strictures are present. Retained capsules may be asymptomatic yet still require surgery, so better...
PSC is rare in the general population but substantially more common in people with IBD, particularly ulcerative colitis, and it raises long-term hepatobiliary risks including cholangiocarcinoma—so knowing how often PSC...
Many people worry that medications taken during pregnancy could affect a child’s long-term health. This large study suggests that prenatal use of acid-suppressive drugs is not clearly linked to a meaningful increase in...
Cure8 found this source from independent.com.mt, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Community and awareness. Open the original article for the...
Faster, accurate diagnosis can let people with Crohn's disease start appropriate treatment sooner and help avoid complications from ongoing inflammation. The article outlines common presenting symptoms and recommended...
Cure8 found this source from newsmax.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Tests and monitoring. Open the original article for the full...
